Возможности ингибиторов ангиотензинпревращающего фермента в клинической практике: фокус на фозиноприл

1. Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
2. ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. http://eurheartj.oxfordjournals.org/content/early/2013/08/28/eurheartj.eht296
3. The 2012 ESC Guidelines on Heart Failure. Eur Heart J 2012; 33: 1703–11; doi:10.1093/eurheartj/ehs138
4. Anderson RJ, Duchin KL, Gore RD et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991; 17: 636–42.
5. Ford NE, Fulmor JE, Nichola PS. Fosinopril monotherapy: relationship between blood pressure reduction and time of administration. Clin Cardiol 1993; 16: 324–30.
6. Tatti P, Pahor M, Byington RP et al. Outcome results of the fosiniprils amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597–603.
7. Zanchetti A, Crepaldi G, Bond MG et al. Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis: Principal Results of PHYLLIS-A Randomized Double-Blind Trial. Stroke 2004; 35: 2807–12.
8 Vetter W. Treatment of senile hypertension. The Fosinopril in the Old Patients Study (FOPS). Am J Hypertension 1997; 10: 255S–61S.
9. Berdah J, Guest M, Salvador M. Study of the efficacy and safety of fosinopril in general practice in 19 435 hypertensive patients (FLIGHT Study). Ann Cardiol Angiol 1998; 10: 169–75. 
10. Zannad F, Chati Z, Guest M et al. Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Studi Investigators. Am Heart J 1998; 136 (4 Pt 1): 672–80.
11. Cleland JG, Tendera M, Adamus J et al. PEP–CHF Investigators The perindopril in elderly people with chronic heart failure (PEP–CHF) study. Eur Heart J 2006; 27 (19): 2338–45.
12. MacLeod CM, Bartley EA, Kripalani KJ et al. Effect of hepatic function on disposition of fosinopril in human. J Clin Pharmacol 1990; 30: 839–44.
13. David D, Jallad N, Germino W et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with history of ACE inhibitor-associated cough. Am J Ther 1995; 2 (10): 806–13.
14. Ford NF et al. Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J Clin Pharmacol 1995; 35: 145–50.
15. Deedwania PC. Clinical profile of fosinopril, a novel phosphinic acid ACE inhibitor, for the treatment of heart failure. Heart Failure 1995; 11: 3.
16. Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект «ТРИ Ф» («ФЛАГ», «ФАСОН», «ФАГОТ»). Сердечная недостаточность. 2003; 4 (5).
17. НOPE study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145–53.
18. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–8.

Д.В.Небиеридзе

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России, Москва